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Duchenne muscular dystrophy usually affects males. However, females are also 
affected in rare instances. Approximately 8% of female Duchenne muscular dys-
trophy (DMD) carriers are manifesting carriers and have muscle weakness to 
some extent. We investigated the clinical features of 3 female patients with dystro-
phinopathy diagnosed by clinical, pathological, and genetic studies at our neuro-
muscular disease clinic. The onset age of manifesting symptoms varied (8-28 
years). Muscle weakness grade varied as follows: patient 1 showed asymmetrical 
bilateral proximal upper and lower extremities weakness, patient 2 showed asym-
metrical bilateral upper extremities weakness similar to scapulohumoral muscular 
dystrophy, and patient 3 had only bilateral asymmetric proximal lower extremities 
weakness. Two patients had familial histories of DMD (their sons were diagnosed 
with DMD), but the 1 remaining patient had no familial history of DMD. The se-
rum creatine kinase level was elevated in all patients, but it was not correlated with 
muscular weakness. An electromyography study showed findings of myopathy in 
all patients. One patient was diagnosed with a DMD carrier by a muscle biopsy 
with an immunohistochemical stain (dystrophin). The remaining 2 patients with 
familial history of DMD were diagnosed by multiplex ligation-dependent probe 
amplification (MLPA). There were inconsistent clinical features in the female car-
riers. An immunohistochemical analysis of dystrophin could be useful for female 
carrier patients. Also, multiplex ligation-dependent probe amplification is essential 
for the diagnosis of a manifesting female carrier DMD in female myopathic pa-
tients because conventional multiplex PCR could not detect the duplication and is 
less accurate compared to MLPA.
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INTRODUCTION    
Two-thirds of mothers of affected males are thought to be Duchenne muscular dystro-
phy (DMD) gene carriers and approximately 8% of female DMD carriers have mus-
cle weakness to some extent and are designated as manifesting DMD carriers.1-3 We 
investigated the clinical features of 3 female myopathic carrier patients with DMD. Manifesting Female Carriers in Patients with Duchenne Muscular Dystrophy
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ic patterns on a dystrophin immunohistochemical stain from 
a muscle biopsy (Fig. 1). The other immunohistochemical 
stain for detecting limb girdle muscular dystrophy and con-
genital myopathy revealed no abnormality. Accordingly, 
she was diagnosed as a DMD carrier. 
Case 2
A 32 year-old woman was admitted with complaints of pro-
gressive limb weakness that started 9 years prior. She had 2 
sons who were diagnosed by exon duplication (exon 52, 
53, 56-61) with DMD. On a neurological examination, she 
showed intellectual disability (IQ = 70) and her bilateral up-
per extremities, especially scapulohumoral lesion, showed 
muscular weakness (right arm abductor, elevator, adductor 
G4°/left arm abductor, elevator, adductor G4+). The power 
of other muscles was within a relatively normal range. 
Gower signs and bilateral calf pseudohypertrophy were not 
observed. Serum CK was mildly elevated (CK: 3708 U/L). 
Cardiac echocardiography showed normal findings, but 
ECG findings revealed the R/S > 1 in Vl, 2 leads, and deep 
Q wave in I, V4-6 leads. An electromyography study re-
vealed spontaneous activity (fibrillation and positive sharp 
waves) and short duration polyphasic potentials in volun-
tary contraction. A conventional multiplex polymerase chain 
reaction (PCR) had negative findings, but a multiplex liga-
tion-dependent probe amplification (MLPA) revealed exon 
duplication at exon 52, 53, 56-61.
Case 3
A 34 year-old woman was admitted with complaints of 
progressive weakness in both legs that started 6 years prior. 
She had 2 sons, who were diagnosed by exon deletion (exon 
43, 44 and 45) with DMD. On a neurological examination, 
she showed intellectual disability (IQ = 78) and her bilater-
al lower extremities showed muscular weakness (right hip 
flexor, hip extensor, knee flexor, knee extensor G3°/left hip 
flexor, hip extensor, knee flexor, knee extensor G4-). The 
power of the other muscles was within a relatively normal 
range. Gower signs and bilateral calf pseudohypertrophy 
were not observed. Serum CK was mildly elevated (CK: 
1289 U/L). Electrocardiography and cardiac echocardiogra-
phy showed no abnormal findings. An electromyography 
study revealed spontaneous activity (fibrillation and posi-
tive sharp waves) and short duration polyphasic potentials 
in voluntary contraction. A conventional multiplex PCR 
had negative findings but a MLPA revealed exon deletion at 
43, 44 and 45.
CASE REPORT
Case 1
A 9 year-old girl was admitted with complaints of slow, 
progressive proximal limb weakness that started 1 year pri-
or. Until the age of 8, she had grown up without abnormali-
ty, developed a normal walking course, and normal cogni-
tive function. There was no familial history of neuromus-
cular disease, including her elder brother. Upon neurological 
examination, she showed normal intelligence and no crani-
al nerve abnormality. However, her bilateral limb-girdle 
muscular power decreased (right arm abductor, arm eleva-
tor, arm adductor, forearm flexor, forearm extensor G4+/left 
arm abductor, arm elevator, arm adductor, forearm flexor, 
forearm extensor G4°/right hip flexor, hip extensor, knee 
flexor, knee extensor G4°/left hip flexor, hip extensor, knee 
flexor, knee extensor G4+). Gower signs and bilateral calf 
muscle pseudohypertrophy were also observed. Liver en-
zymes, serum CK, lactate dehydrogenase, and aldolase 
were elevated (AST: 97 IU/L; ALT: 225 IU/L; and CK: 456 
1 U/L, CK-MB 225 U/L, LDH 1714 IU/L, and Aldolase 
16.4 U/mL). The patient also showed normal findings for 
viral hepatitis markers and arterial blood gas analysis. Elec-
trocardiography and cardiac echocardiography showed no 
abnormal findings. An electromyography study revealed 
spontaneous activity (positive sharp waves) and short dura-
tion polyphasic potentials in voluntary contraction. We car-
ried out a muscle biopsy on the left vastus lateralis muscle 
because limb-girdle muscular dystrophy was suspected as 
the patient was female and did not have a familial history of 
DMD. The expression of dystrophin protein showed mosa-
Fig. 1. Skeletal muscle, left vastus laterals: increased size variability and 
degenerating fibers were revealed. Dystrophin immunostaining revealed a 
mosaic distribution of positive and negative fibers on C-terminals.Tae-Jin Song, et al.
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the deletions in male patients, but duplications are not iden-
tified in DMD.10-12 However, the MLPA method has turned 
out to be reliable and accurate for identifying duplications 
and deletions in DMD.13,14 The MLPA technique could in-
crease mutation pick-up rate by 33% rather than PCR.14 
Moreover, the technique could confidently identify carrier 
individuals.14 In our cases, exon duplication detected in case 
2, on the other hand, exon deletion also detected in case 3 
but the PCR could not detect genetic abnormality. These re-
sults support that MLPA is essential for diagnosis of mani-
festing female carrier DMD in female myopathic patients 
because conventional multiplex PCR could not detect the 
duplication and is less accurate compared to MLPA. 
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